S

SSY Group Ltd
HKEX:2005

Watchlist Manager
SSY Group Ltd
HKEX:2005
Watchlist
Price: 3.73 HKD -2.1% Market Closed
Market Cap: 11B HKD
Have any thoughts about
SSY Group Ltd?
Write Note

SSY Group Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

SSY Group Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
S
SSY Group Ltd
HKEX:2005
Income from Continuing Operations
HK$1.4B
CAGR 3-Years
29%
CAGR 5-Years
6%
CAGR 10-Years
13%
G
Grand Pharmaceutical Group Ltd
HKEX:512
Income from Continuing Operations
HK$2.4B
CAGR 3-Years
2%
CAGR 5-Years
21%
CAGR 10-Years
34%
U
United Laboratories International Holdings Ltd
HKEX:3933
Income from Continuing Operations
ÂĄ2.9B
CAGR 3-Years
37%
CAGR 5-Years
27%
CAGR 10-Years
18%
Sino Biopharmaceutical Ltd
HKEX:1177
Income from Continuing Operations
ÂĄ4.9B
CAGR 3-Years
-26%
CAGR 5-Years
-15%
CAGR 10-Years
12%
C
China Resources Pharmaceutical Group Ltd
HKEX:3320
Income from Continuing Operations
HK$13.3B
CAGR 3-Years
32%
CAGR 5-Years
10%
CAGR 10-Years
N/A
H
HUTCHMED (China) Ltd
HKEX:13
Income from Continuing Operations
-$42.2m
CAGR 3-Years
37%
CAGR 5-Years
13%
CAGR 10-Years
N/A
No Stocks Found

SSY Group Ltd
Glance View

Market Cap
11.1B HKD
Industry
Pharmaceuticals

SSY Group Ltd. is an investment holding company, which engages in the research, development, and manufacture of pharmaceutical products. The company employs 4,800 full-time employees The company went IPO on 2005-12-20. The Company’s main products include finished medicines of mainly intravenous infusion solution to hospitals and distributors, bulk pharmaceuticals and medical materials. The Company’s products mainly include non-PVC (Polyvinyl chloride) soft bag infusion solution, PP (Polypropylene) plastic bottle infusion solution and Glass bottle infusion solution. The Company’s products also include Hydrochloride Betahistine, Hydrochloride Ambroxol and Doxofylline as well as bulk pharmaceuticals including caffeine, theophylline, aminophylline, metronidazole and nifedipine.

Intrinsic Value
5.41 HKD
Undervaluation 31%
Intrinsic Value
Price
S

See Also

What is SSY Group Ltd's Income from Continuing Operations?
Income from Continuing Operations
1.4B HKD

Based on the financial report for Jun 30, 2024, SSY Group Ltd's Income from Continuing Operations amounts to 1.4B HKD.

What is SSY Group Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
13%

Over the last year, the Income from Continuing Operations growth was 12%. The average annual Income from Continuing Operations growth rates for SSY Group Ltd have been 29% over the past three years , 6% over the past five years , and 13% over the past ten years .

Back to Top